您好,欢迎来到科研在线!科研采购 · 选型 · 实验方法
首页产品库品牌馆产品类别品牌新闻会议会展产品试用求职招聘资讯专题教程
PRO / Antibodies

In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody

In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody

英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody(克隆 29F.1A12 / B20-4.1.1) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 PD1(别名 PD-1 等)。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。

生物试剂 供应商 上海英诺赛图 ↗ 型号 514101 更新 2026-11-12
参考价格区间
¥11,865
含税参考价,实际以配置与渠道报价为准
本条目供应商 上海英诺赛图原厂 1865个条目 进入企业主页

01产品图片

02产品简介

英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody(克隆 29F.1A12 / B20-4.1.1) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 PD1(别名 PD-1 等)。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。

03产品介绍

规格与货号

514001 | 1 mg | ¥11,865

514002 | 5 mg | ¥40,341

514003 | 25 mg | ¥121,023

514101 | 1 mg | ¥11,865

514102 | 5 mg | ¥40,341

514103 | 25 mg | ¥121,023

514301 | 1 mg | ¥11,865

514302 | 5 mg | ¥40,341

514303 | 25 mg | ¥121,023

514401 | 1 mg | ¥11,865

514402 | 5 mg | ¥40,341

514403 | 25 mg | ¥121,023

514601 | 1 mg | ¥11,865

514602 | 5 mg | ¥40,341

514603 | 25 mg | ¥121,023

514701 | 1 mg | ¥11,865

514702 | 5 mg | ¥40,341

514703 | 25 mg | ¥121,023

Product Details

Application|Functional assay, Neutralization, animal model study

Product Description|In Vivo Grade Recombinant Anti-mouse PD-1 / VEGF-A Bispecific Antibody

Regulatory Status|RUO

Endotoxin

Storage Conditions|4ºC

Recommended Usage|This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.

See All Formats|Clone 29F.1A12 / B20-4.1.1

Background Information

Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor expressed primarily on activated T cells, B cells, and some myeloid cells. It plays a key role in maintaining immune tolerance by downregulating T cell activation when engaged by its ligands PD-L1 or PD-L2 on antigen-presenting cells or tumor cells. Structurally, PD-1 is a type I transmembrane glycoprotein composed of an extracellular immunoglobulin-like domain, a transmembrane region, and an intracellular tail containing immunoreceptor tyrosine-based inhibitory (ITIM) and switch motifs (ITSM). When PD-1 binds to PD-L1 or PD-L2, it initiates inhibitory signaling through SHP-2 phosphatase recruitment, dampening T cell proliferation, cytokine production, and cytotoxic function. In cancer, chronic PD-1 engagement leads to T cell exhaustion, allowing tumor cells to escape immune destruction. This has made PD-1 a central therapeutic target in immuno-oncology, giving rise to checkpoint inhibitors like pembrolizumab and nivolumab.

Vascular Endothelial Growth Factor A (VEGF-A) is a fundamental regulator of angiogenesis, promoting endothelial cell proliferation, migration, and vascular permeability. It binds to tyrosine kinase receptors VEGFR-1 and VEGFR-2 on endothelial cells, driving new blood vessel formation under physiological conditions such as wound healing and tissue repair. In cancer, VEGF-A is frequently overexpressed, leading to aberrant, leaky, and immunosuppressive vasculature that supports tumor growth and hinders immune cell infiltration. By sustaining hypoxic and immunosuppressive microenvironments, VEGF-A contributes not only to tumor progression but also to resistance against immune checkpoint blockade.

A bispecific antibody targeting PD-1 and VEGF-A offers a powerful strategy to simultaneously reinvigorate exhausted T cells and normalize the tumor vasculature. Dual blockade can act synergistically: inhibition of VEGF-A enhances immune cell infiltration by improving vessel structure and reducing hypoxia, while PD-1 blockade restores effector T cell function and anti-tumor immunity. This combination addresses two critical barriers to effective cancer immunotherapy: immune suppression and poor immune access to tumors. Moreover, delivering both mechanisms in a single bispecific antibody may optimize pharmacokinetics, improve co-localization within the tumor microenvironment, and reduce systemic toxicity compared with separate therapies. Preclinical and early clinical studies suggest that PD-1 × VEGF-A bispecifics could yield superior efficacy in “cold” tumors that respond poorly to checkpoint inhibitors alone by converting them into “hot,” inflamed microenvironments more amenable to immune attack. Thus, such bispecifics represent a rational evolution in cancer immunotherapy, bridging vascular and immune modulation for more durable anti-tumor responses.

Data Sheets

Cat # Size Price Quantity 5141011 mg Add to Cart5141025 mg Add to Cart51410325 mg Add to Cart

04完整参数表

参数由厂商资料整理,采购前请以最终报价单与技术协议为准。

包装规格1 mg
Clone29F.1A12 / B20-4.1.1
Host SpeciesCHO cells
ReactivityMouse
FormatLiquid
Target NamePD1, PD-1, PDCD1, CD279, SLEB2, Vascular endothelial growth factor, VEGF-A, VEGFA, VEGF
Product DescriptionIn Vivo Grade Recombinant Anti-mouse PD-1 / VEGF-A Bispecific Antibody
IsotypeMouse IgG2c LALAPG Kappa
Antibody TypeRecombinant
Regulatory StatusRUO
Purity>95% by reducing SDS-PAGE
Storage Conditions4ºC
GradeIn vivo
Recommended UsageThis product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
RRIDAB_3739417
目录价¥11,865

05荣誉与资质

该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。

  • 营业执照未上传
  • 品牌授权未上传
  • 产品检测报告未上传
会员身份
收费会员
经营身份
原厂
成立年份
2020 年
所在地
上海
收录条目
1865 个
平台核验
平台代管
向品牌方索取资质文件

06品牌与供应商

上海英诺赛图 原厂
InnoCyto

以可信赖的细胞研究试剂,助力科研突破

进入企业主页
1865 本目录条目
产地 / 总部上海市浦东新区
成立年份2020 年
本目录主营生化试剂 / 蛋白与抗体

InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。

售后与服务

品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。

引用此条目 产品目录 · 更新于 2026-11-12
科研在线(TeleVM). In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody(514101)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd279-pd1-vegf-a-bispecific-antibody-514101.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody(514101). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd279-pd1-vegf-a-bispecific-antibody-514101.html
@misc{biocsp_item_in_vivo_star_anti_mouse_cd279_pd1_vegf_a_bispecific_antibody_514101,
  title        = {In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody(514101)},
  author       = {{科研在线}},
  year         = {2026},
  howpublished = {产品目录},
  note         = {更新于 2026-11-12,产品目录},
  url          = {https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd279-pd1-vegf-a-bispecific-antibody-514101.html}
}

GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。

许可:CC BY-NC 4.0 · 转载注明来源
获取正式报价

In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody

提交后由平台转给品牌方,通常 1 个工作日内联系。不需要注册。